Table 4.
Immunocompromised Status and Medication for HIV-negative Cohort
| HIV-negative Cohort N = 19 | |
|---|---|
| CLL | 3 (15.8%) |
| Organ transplantation | 8 (42.1%) |
| Kidney | 5/8 |
| Lung | 2/8 |
| Liver | 1/8 |
| Autoimmune disease | 5 (26.3%) |
| SLE | 2/5 |
| Sarcoidosis | 2/5 |
| Neurosarcoidosis | 1/5 |
| Immunosuppressants | 1 (5.3%) |
| Immunocompetent | 3 (15.8%) |
| Sex/Age | Condition | Immunosuppressant Medication | Intervention | Time to Development of Cryptococcal Infection After Immunocompromised Status |
|---|---|---|---|---|
| M63 | CLL, small cell lymphoma | Lenalidomide, rituximab | NA | 1 y after transplant |
| M75 | CLL | Ibrutinib | NA | 7 y after diagnosis of CLL |
| M57 | CLL | Ibrutinib, Obinutuzumab | NA | 1 y after diagnosis of CLL |
| M44 | Lung transplant | Tacrolimus, oral prednisone | NA | 3 y after transplant |
| M64 | Lung transplant | Mycophenolate mofetil, oral prednisone | NA | 1 y after transplant |
| M64 | Liver transplant | Tacrolimus, oral prednisone | NA | 5 y after transplant |
| M63 | Kidney transplant | Cyclosporin, oral prednisone | NA | 1 y after transplant |
| F45 | Kidney transplant | Oral prednisone, eculizumab trial | NA | 2 y after transplant |
| F47 | Kidney transplant | Graft failure, oral prednisone, tacrolimus | VPS | 1 y after transplant |
| M60 | Kidney transplant with ESRD | Tacrolimus | VPS Deceased | 4 y after transplant |
| M74 | Kidney transplant | Tacrolimus, oral prednisone, Leflunomide | NA | 2 y after transplant |
| M44 | Sarcoidosis in 2003 | Oral prednisone | NA | 10 y after diagnosis of sarcoidosis |
| M41 | Sarcoidosis | Oral prednisone | NA | 6 y after diagnosis of sarcoidosis |
| M35 | Sarcoidosis with CNS involvement | Oral prednisone | Extraventricular drain followed by VPS | 4 y after diagnosis of sarcoidosis |
| F25 | SLE, APLS, ARF | Oral prednisone, mycophenolate mofetil, cyclophosphamide, rituximab | NA | 5 y after diagnosis of SLE |
Abbreviations: APLS, antiphospholipid syndrome; ARF, acute renal failure; CLL, chronic lymphocytic leukemia; CNS, central nervous system; ESRD, end-stage renal disease; NA, not available; SLE, systemic lupus erythematosus; VPS, ventriculoperitoneal shunting.